

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Notice of Extraordinary General Meeting in Enzymatica AB (publ)

The extraordinary general meeting of Enzymatica AB (publ), reg. no. 556719-9244 (the “Company”), will be held on 6 August 2024 at 13:00, Ideon Science Park, Scheelevägen 19, 223 70 in Lund.

Notification etc.

Those who wish to participate in the extraordinary general meeting must:

- (i) be listed as a shareholder in the presentation of the share register prepared by Euroclear Sweden AB concerning the circumstances as per the record date of 29 July 2024; and
- (ii) give notice of intent to participate no later than 31 July 2024. Notification shall be made either in writing to Enzymatica AB, Att: Sriwarint Olsson, Ideon Science Park, Scheelevägen 19, SE-223 70 Lund, or by email, sriwarint.olsson@enzymatica.com.

The notice shall include full name, personal identification number or corporate registration number, address and daytime telephone number and, where appropriate, information about representative, proxy and assistants. The number of assistants may not be more than two (2). The notification should, where appropriate, be accompanied by proxies, registration certificates and other documents of authority.

In order to be entitled to participate in the meeting, a shareholder whose shares are registered in the name of a nominee must, in addition to giving notice of participation in the extraordinary general meeting, register its shares in its own name at Euroclear Sweden AB so that the shareholder is listed in the share register as of the record date of 29 July 2024. Such re-registration may be temporary (so called voting rights registration), and a request for such voting rights registration shall be made to the nominee, in accordance with the nominee’s routines, at such time in advance as decided by the nominee. Voting rights registration that has been made by the nominee no later than 31 July 2024, will be taken into account in the presentation of the share register.

Proxies etc.

If a shareholder is to vote through a proxy, a written, dated and signed proxy by the shareholder must be provided at the general meeting. The proxy may not be older than one (1) year, unless longer validity (maximum of five (5) years) is stated in the proxy. If the proxy is issued by a legal entity, the current registration certificate or equivalent authorisation document for the legal entity must also be provided. To facilitate an easier passing, a copy of the proxy and other documents of authority should be enclosed with the registration for the general meeting. Proxy forms will be kept available on the Company’s website, www.enzymatica.se, and at the Company’s head office and will be sent by post to shareholders who contact the Company and state their address.

Proposed agenda

1. Opening of the meeting
2. Election of chairman of the meeting

3. Drafting and approval of the voting list
4. Approval of the agenda
5. Election of one or two persons to countersign the minutes
6. Determination as to whether the meeting has been duly convened
7. Approval of the board of directors' resolution on a rights issue of new shares
8. Closing of the meeting

Resolution proposals

Item 2 – Election of chairman of the meeting

The board of directors proposes that attorney at law Marcus Nivinger, Setterwalls Law Firm, shall be elected chairman of the meeting.

Item 7 – Approval of the board of directors' resolution on a rights issue of new shares

The board of directors proposes that the meeting approves the board of directors' resolution from 18 July 2024, to increase the Company's share capital by a maximum amount of SEK 2,774,117.32 through the issue of a maximum number of 69,352,888 shares, each with a quota value of SEK 0.04.

The following terms and conditions shall apply to the rights issue.

1. The shareholders of the Company shall have preferential rights to subscribe for the new shares in relation to the number of shares previously held. For each share held on the record date, the shareholder receives one subscription right, whereby five (5) subscription rights entitle to subscribe for two (2) new shares.
2. If not all the shares are subscribed for by exercise of subscription rights, the Board of Directors shall resolve on allotment of shares subscribed for without the exercise of subscription rights up to the maximum amount of the share issue. Such shares shall firstly be allotted to those who have also subscribed for shares by exercise of subscription rights, regardless of them being shareholders on the record date or not, pro rata in relation to the number of subscription rights which each person has exercised for subscription. Secondly, such shares shall be allotted to others, pro rata in relation to their applied interest. To the extent that allotment in accordance to the above cannot be made pro rata, allotment shall be made by drawing of lots. Any remaining shares shall be allotted to those who have guaranteed the new share issue, pro rata in relation to the guaranteed amount.
3. The record date for determining which shareholders shall be entitled to subscribe for new shares on a preferential basis shall be 26 August 2024.
4. The subscription price is SEK 1.90 per share which in the case of full subscription provides issuing proceeds of up to approximately MSEK 131.8.
5. Subscription for new shares by exercise of subscription rights shall be made by simultaneously cash payment during the period as from 28 August 2024 up to and including 11 September 2024. Subscription for new shares without the exercise of subscription rights shall take place during the same period on a separate subscription

list. Payment for new shares subscribed for without the exercise of subscription rights shall be made in cash no later than on the second bank day from dispatch of the contract note setting forth the allotment of shares. The Board of Directors shall be entitled to extend the period for subscription and payment.

6. The share premium shall be transferred to the unrestricted premium reserve.
7. The new shares shall entitle to dividends as from the first record date for dividends following registration of the new share issue with the Swedish Companies Registration Office.
8. Trading with subscription rights will take place during the period from 28 August 2024 until, and including 6 August 2024. Trading in BTA (Paid Subscribed Shares) will take place from 28 August 2024 until and including around 20 September 2024.

It was noted that the documents in accordance with Chapter 13, section 6 of the Swedish Companies Act were duly presented.

The Board of Directors, or a person appointed by the Board of Directors, shall be authorised to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office or Euroclear Sweden AB.

Available documents

Documents that shall be made available prior to the extraordinary general meeting pursuant to the Swedish Companies Act will be made available at the Company and at the Company's website, www.enzymatica.se, at least two weeks prior to the extraordinary general meeting. The documents will also be sent free of charge to shareholders who so request and provide their address to the Company. In other respects, the board of directors' complete proposals for resolutions are stated in the notice.

Information at the extraordinary general meeting

The board of directors and CEO shall, if any shareholder so requests and the board of directors believes that it can be done without material harm to the Company, provide information regarding circumstances that may affect the assessment of an item on the agenda. The obligation to provide information includes the Company's relation to other Companies within the group, the consolidated accounts and such relationships regarding subsidiaries as is referred to in the preceding sentence.

Shareholders who wish to submit a question in advance can do so by mail to Sriwarint Olsson at the address Enzymatica AB, Att: "EGM 2024", Ideon Science Park, Scheelevägen 19, SE-223 70 Lund or via email to sriwarint.olsson@enzymatica.com. Submissions should include the name of the shareholder including such shareholder's personal or organisation number. It is also recommended that the submission includes the shareholder's postal address, email address and telephone number.

It was noted that the documents in accordance with Chapter 13, section 6 of the Swedish Companies Act were duly presented.

The Board of Directors, or a person appointed by the Board of Directors, shall be authorised to make any minor adjustments required to register the resolution with the Swedish Companies Registration Office or Euroclear Sweden AB.

Available documents

Documents that shall be made available prior to the extraordinary general meeting pursuant to the Swedish Companies Act will be made available at the Company and at the Company's website, www.enzymatica.se, at least two weeks prior to the extraordinary general meeting. The documents will also be sent free of charge to shareholders who so request and provide their address to the Company. In other respects, the board of directors' complete proposals for resolutions are stated in the notice.

Information at the extraordinary general meeting

The board of directors and CEO shall, if any shareholder so requests and the board of directors believes that it can be done without material harm to the Company, provide information regarding circumstances that may affect the assessment of an item on the agenda. The obligation to provide information includes the Company's relation to other Companies within the group, the consolidated accounts and such relationships regarding subsidiaries as is referred to in the preceding sentence.

Shareholders who wish to submit a question in advance can do so by mail to Sriwarint Olsson at the address Enzymatica AB, Att: "EGM 2024", Ideon Science Park, Scheelevägen 19, SE-223 70 Lund or via email to sriwarint.olsson@enzymatica.com. Submissions should include the name of the shareholder including such shareholder's personal or organisation number. It is also recommended that the submission includes the shareholder's postal address, email address and telephone number.

Shares and votes in the Company

The total number of shares and votes in the Company amounts as per the date of this notice to 173,382,220. The Company does not hold any own shares.

Processing of personal data

For information on how your personal data is processed, the Company refers to the integrity policy available on Euroclear Sweden AB's [website](#).

Lund in July 2024

Enzymatica AB (publ)

The Board of Directors